Free Trial

Exact Sciences (EXAS) Stock Price, News & Analysis

Exact Sciences logo
$52.82 -1.05 (-1.94%)
Closing price 07/3/2025 03:12 PM Eastern
Extended Trading
$52.82 0.00 (0.00%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Exact Sciences Stock (NASDAQ:EXAS)

Key Stats

Today's Range
$52.90
$54.23
50-Day Range
$44.79
$58.08
52-Week Range
$39.97
$72.83
Volume
1.67 million shs
Average Volume
2.58 million shs
Market Capitalization
$9.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.40
Consensus Rating
Moderate Buy

Company Overview

Exact Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

EXAS MarketRank™: 

Exact Sciences scored higher than 98% of companies evaluated by MarketBeat, and ranked 82nd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 19 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Exact Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Exact Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Exact Sciences are expected to grow in the coming year, from ($0.58) to $0.50 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exact Sciences is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exact Sciences is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Exact Sciences has a PEG Ratio of 11.50. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Exact Sciences has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Exact Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    4.25% of the float of Exact Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Exact Sciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exact Sciences has recently decreased by 25.68%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Exact Sciences does not currently pay a dividend.

  • Dividend Growth

    Exact Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.25% of the float of Exact Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Exact Sciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exact Sciences has recently decreased by 25.68%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Exact Sciences has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Exact Sciences this week, compared to 11 articles on an average week.
  • Search Interest

    Only 8 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $170,612.00 in company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of Exact Sciences is held by insiders.

  • Percentage Held by Institutions

    88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exact Sciences' insider trading history.
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

William Blair Predicts Increased Earnings for Exact Sciences
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
EXAS - Exact Sciences Corp Financials - Morningstar
See More Headlines

EXAS Stock Analysis - Frequently Asked Questions

Exact Sciences' stock was trading at $56.19 at the beginning of the year. Since then, EXAS shares have decreased by 6.0% and is now trading at $52.8150.

Exact Sciences Corporation (NASDAQ:EXAS) issued its quarterly earnings results on Thursday, May, 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.16. The company's revenue for the quarter was up 10.9% compared to the same quarter last year.
Read the conference call transcript
.

Exact Sciences subsidiaries include these companies: Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and others.

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/01/2025
Today
7/04/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EXAS
Employees
7,000
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$70.40
High Stock Price Target
$90.00
Low Stock Price Target
$54.00
Potential Upside/Downside
+33.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.95
Research Coverage
22 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
11.5
Net Income
-$1.03 billion
Pretax Margin
-36.38%

Debt

Sales & Book Value

Annual Sales
$2.76 billion
Cash Flow
$5.52 per share
Price / Cash Flow
9.56
Book Value
$12.98 per share
Price / Book
4.07

Miscellaneous

Free Float
186,374,000
Market Cap
$9.96 billion
Optionable
Optionable
Beta
0.95

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:EXAS) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners